Business Wire

CITY-OF-ESPOO

Share
Annual Eurocities Conference Held by Espoo Focuses on Cities’ Climate Leadership

At the three-day conference that brings the management of European cities together, the topics discussed include the inclusion of young people, co-creation and cities’ leadership in the work against climate change. The theme of the annual conference, An Era of New Beginnings, consists of three parts, Dream, Act and Lead, through which these topics are studied. The conference attendees include city leadership from Oslo, Rotterdam, Helsinki, Brussels, Stockholm and Munich, among other cities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220530005019/en/

On Friday, one of the keynote speakers will be Executive Vice-President of the European Commission Frans Timmermans , who will introduce the discussion on climate-neutral cities.

“Cities play a key role in the progress towards the EU’s climate goals and building a sustainable future. The annual conference also strengthens the dialogue between cities and the European Commission. However, achieving the goals will be impossible if cities cannot extensively involve operators from all sectors of society. Co-creation and cooperation between the public and private sector are some of the overarching themes of the conference, in addition to climate leadership and young people’s inclusion,” says Milla Ovaska , Head of International Affairs at the City of Espoo.

As a part of the conference and the European Year of Youth, Espoo is organising the Future Mentors programme in which young people living in European cities engage in dialogue with the policymakers of their cities. This is called reverse mentoring.

“We wanted to provide young people with an opportunity to voice their dreams, wishes and concerns about the future of their home city. The decisions that we are making now will have long-term influence, and young people will be the ones living in the future we create. We would like the programme to encourage policymakers to engage in dialogue and give space to new ways of thinking,” says Marianne Julkunen , Partnership Coordinator.

Eurocities Awards to best practices of resident inclusion

On the evening of Thursday 9 June, the conference programme includes the Eurocities Awards ceremony , which showcases the member cities’ projects that have succeeded best in involving their residents and influencing their quality of life. This year’s awards will be given in three categories: ‘Future generations transforming the cities,’ ‘Skills and competences for the future’ and ‘Scalable solutions for positive climate impact.’ The winners will be selected by a five-person jury.

Representatives of the media are cordially invited to attend the annual Eurocities conference on-site at Espoo, Finland. The conference is also available virtually on its website .

#Eurocities2022
#FutureMentors2022

The conference has been created in collaboration with various organisations, all relevant to building future-proof cities and societies. The main partners are Aalto University and VTT. You can find all partners at: eurocities2022.eu/partners .

Eurocities is the key network of European cities for Espoo. Eurocities supervises interests at the level of the EU, generates information about the EU’s funding application rounds and EU legislation, and functions as a peer learning platform for its member cities.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye